Prostate Cancer Trials
Prostate
Recruiting
ANZadapt
ANZUP 2101
NSW | VIC | QLD | SA | WA
Phase II randomised controlled trial of patient-specific adaptive versus continuous Abiraterone or eNZalutamide in metastatic castration-resistant prostate cancer
Prostate
In Follow-up
DASL-HiCaP
ANZUP 1801
NSW | VIC | QLD | SA | TAS | WA | NZ | Ireland | Canada | USA
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
Prostate
Recruiting
DIPPER
ANZUP 2002
NSW | VIC | QLD
A multi-centre, randomised phase 2 clinical trial of early salvage radiotherapy versus surveillance for biochemical recurrence after radical prostatec…
Prostate
In Follow-up
ENZA-p
ANZUP 1901
NSW | VIC | QLD | SA | WA
A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in people with metastatic castration-resistant prostate cancer treated with enzalutamide.
Prostate
In Follow-up
ENZAMET
ANZUP 1304
NSW | VIC | QLD | NT | SA | TAS | WA | NZ | UK | Ireland | Canada | USA
Enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: a randomised phase III trial
Prostate
In Follow-up
ENZARAD
ANZUP 1303
NSW | VIC | QLD | SA | TAS | WA | NZ | UK | Ireland | Belgium | USA | Spain | Austria | Slovenia
Enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: a randomised phase III trial
Prostate
In Follow-up
EVOLUTION
ANZUP 2001
NSW | VIC | SA | WA
Phase II Study of Radionuclide 177Lu-PSMA Therapy versus 177Lu-PSMA in Combination with Ipilimumab and Nivolumab for people with Metastatic Castration Resistant Prostate Cancer
Prostate
Recruiting
GUIDE
ANZUP 1903
NSW | VIC
A randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care (SOC) docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
Prostate
In Follow-up
proPSMA
HREC/16/PMCC/130
NSW | VIC | QLD | SA | WA
A prospective randomised multi-centre study of the impact of Ga-68 PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy
Prostate
In Follow-up
TheraP
ANZUP 1603
NSW | VIC | QLD | SA | WA
A randomised phase II trial of 177Lu-PSMA617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer
Prostate
In Follow-up
#UpFrontPSMA
18/047
NSW | VIC | QLD | SA | WA
A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer
Prostate
Recruiting
NINJA
TROG 18.01
NSW | VIC | QLD | SA | WA | NZ
Novel Integration of new prostate radiation therapy schedules with adjuvant androgen deprivation